Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II multicenter study of RY_SW01 cell injection for systemic sclerosis
CTR20232866Phase 2Completed
- Sponsor
- Ruiyuan Biotech
- Start
- Sep 2023
- Modality
- Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of 89zr-oxine-ry_sw01, sponsored by Ruiyuan Biotech. Started Sep 2023; status: completed.
02
Drugs
89zr-oxine-ry_sw01
Beyond the preview
Go deeper on CTR20232866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232866.